Sort by
Refine Your Search
-
Listed
-
Country
-
Program
-
Employer
-
Field
-
About us UCL School of Pharmacy is one of the world’s leading centres of excellence for pharmaceutical science, education and professional engagement, ranked third in the world by QS (2025, Pharmacy
-
be found on our website https://www.ucl.ac.uk/biosciences This is an exciting opportunity to join the Cox Lab in the UCL Centre for Integrative Anatomy. The successful applicant will conduct research
-
, based in the UK DRI at UCL, investigates glia-immune mechanisms of synapse loss in age-related neurodegenerative diseases, including Alzheimer’s and Parkinson’s. We study how the brain’s immune system
-
About us The Division of Biosciences at UCL is one of the world's foremost centres for research and teaching in the biological sciences. We have an outstanding international reputation and a
-
About us The mission of the UCL GOS Institute of Child Health is to maximise and advocate for the holistic health of all children, young people and the adults they will become, through world-class
-
About us The UCL Laboratory for Molecular Cell Biology (LMCB, http:/www.ucl.ac.uk/lmcb) is an internationally renowned, multidisciplinary, molecular and cell biology department, located in the heart
-
of working in a research team or in neurodegeneration is desirable. The post is graded as UCL Grade 7 with salary in the range £9,020.60 - £10,517.20 (i.e., 20% of £45,103 - £52,586) per annum
-
structures to support this work. What we offer As well as the exciting opportunities this role presents, we also offer great benefits. Please visit https://www.ucl.ac.uk/work-at-ucl/rewards-and-benefits
-
The UCL Huntington’s Disease Centre is uniquely placed world-wide to translate mechanistic insights to ‘first in human’ studies. It combines sophisticated cell-based systems with rigorously
-
, architecture, and policy. This post is available at grade 6B (£39,148 - £41,833 pa) or grade 7 (£45,103 - £52,586 pa) depending on the qualifications and is funded until 31/10/2026 in the first instance. About